Retatrutide Shows Promise for Glycemic Control and Weight Reduction in Type 2 Diabetes

Phase 3 trial results for the investigational drug retatrutide demonstrate significant improvements in glycemic control and body weight for adults with type 2 diabetes. The once-weekly triple hormone receptor agonist helped a notable percentage of participants achieve normal HbA1c levels without severe hypoglycemia. These findings suggest a potential new therapeutic option for managing type 2 diabetes.